SCHEMBL3917191

SCHEMBL3917191

Cc1ccc(SS(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 1/20 1.00
G6PD P11413 2/20 0.53
GAA P10253 2/20 0.52
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA12 O43570 1/20 0.48
CA3 P07451 1/20 0.48
CA6 P23280 1/20 0.48
CA5A P35218 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA5B Q9Y2D0 1/20 0.48
BCHE P06276 7/20 0.47
ACHE P22303 7/20 0.47
TLR9 Q9NR96 1/20 0.46
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46
ALOX12 P18054 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28229835 0.90 DNMT1 (0.81) DNMT1G6PDGAACA1CA2
SCHEMBL10330810 0.90 DNMT1 (0.81) DNMT1G6PDGAACA1CA2
SCHEMBL10330809 0.90 DNMT1 (0.81) DNMT1G6PDGAACA1CA2
SCHEMBL11290137 0.90 DNMT1 (0.81) DNMT1G6PDGAACA1CA2
SCHEMBL7115923 0.86 DNMT1 (0.73) DNMT1GAACA1CA2CA12
SCHEMBL23312332 0.79 DNMT1 (0.63) DNMT1G6PDCA1CA2CA7
SCHEMBL28711548 0.78 DNMT1 (0.64) DNMT1G6PDGAACA1CA2
SCHEMBL2038233 0.78 DNMT1 (0.64) DNMT1G6PDGAACA1CA2
SCHEMBL733650 0.78 DNMT1 (0.64) DNMT1G6PDGAACA1CA2
SCHEMBL7531692 0.77 DNMT1 (0.63) DNMT1GAACA1CA2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117964529-A Method for synthesizing E-alkenyl thioether compound 江苏海洋大学 2024-05-03 CN disclosed
US-9657027-B2 Processes for making hydrocodone, hydromorphone and their derivatives JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2017-05-23 US disclosed
US-9657028-B2 Processes for making hydrocodone, hydromorphone and their derivatives JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2017-05-23 US disclosed
US-20160137656-A1 PROCESSES FOR MAKING HYDROCODONE, HYDROMORPHONE AND THEIR DERIVATIVES JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2016-05-19 US disclosed
US-20160137655-A1 PROCESSES FOR MAKING HYDROCODONE, HYDROMORPHONE AND THEIR DERIVATIVES JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2016-05-19 US disclosed
US-9273060-B2 Processes for making hydrocodone, hydromorphone and their derivatives JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2016-03-01 US disclosed
US-20150252052-A1 PROCESSES FOR MAKING HYDROCODONE, HYDROMORPHONE AND THEIR DERIVATIVES JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2015-09-10 US disclosed
US-20090221711-A1 TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS WYETH (US) 2009-09-03 US disclosed
US-7550629-B2 4-chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]benzenesulfonamide; 4-cyano-N-(3,3,3-trifluoro-1-hydroxymethyl-2-trifluoromethyl-propyl)-benzenesulfonamide; Alzheimer's Disease, amyloid angiopathy, systemic amyloidosis, mild cognitive impairment and Down's syndrome WYETH (US) 2009-06-23 US disclosed
US-20090117346-A1 PHOTOSENSITIVE MATERIAL FOR FORMING CONDUCTIVE FILM, CONDUCTIVE FILM, LIGHT TRANSMITTING ELECTROMAGNETIC WAVE SHIELDING FILM AND METHOD FOR MANUFACTURING THE SAME FUJIFILM CORPORATION (JP) 2009-05-07 US disclosed
US-20070249722-A1 Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors WYETH (US) 2007-10-25 US disclosed
US-20070249723-A1 Methods for preparing sulfonamide compounds WYETH (US) 2007-10-25 US disclosed
US-7220537-B2 Silver halide emulsion silver halide photographic sensitive material and method of image formation KONICA MINOLTA PHOTO IMAGING, INC. (JP) 2007-05-22 US disclosed
US-7163784-B2 Silver halide emulsion, and silver halide color photographic material using the same KONICA MINOLTA PHOTO IMAGING, INC. (JP) 2007-01-16 US disclosed
US-7163784-B2 Silver halide emulsion, and silver halide color photographic material using the same KONICA MINOLTA PHOTO IMAGING, INC. (JP) 2007-01-16 US disclosed
US-6559170-B1 Compounds are useful as fungicides in plants DOW AGROSCIENCE LLC 2003-05-06 US disclosed
EP-1237870-A1 PYRIDINE DERIVATIVES HAVING FUNGICIDAL ACTIVITY AND PROCESSES TO PRODUCE AND USE THE SAME Dow AgroSciences LLC (US) 2002-09-11 EP disclosed
WO-2001044196-A1 PYRIDINE DERIVATIVES HAVING FUNGICIDAL ACTIVITY AND PROCESSES TO PRODUCE AND USE THE SAME DOW AGROSCIENCES, LLC (US) 2001-06-21 WO disclosed
EP-0538898-A2 Cytotoxic bicyclo (7.3.1)-tridec-4-ene-2,6-diyne compounds and process for the preparation thereof Bristol-Myers Squibb Company (US) 1993-04-28 EP disclosed
EP-0454146-A1 Cytotoxic bicyclo[7.3.1] tridec-4-ene-2,6-diyne compounds and process for the preparation thereof Bristol-Myers Squibb Company (US) 1991-10-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221711-A1 TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS APP, PSEN1, BACE1 DNMT1 3734/4885G6PD 1814/4885GAA 849/4885
US-20070249722-A1 Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors APP, PSEN1, BACE1 DNMT1 3734/4885G6PD 1814/4885GAA 849/4885
US-20070249723-A1 Methods for preparing sulfonamide compounds PNISR, RRM1, MRPS27 DNMT1 1502/4885G6PD 1495/4885GAA 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.